Perspective Therapeutics Inc (CATX)

[stealthways]

2. AF writes "IsoRay also plays rope-a-dope with the five-year overall survival rate of 100% for Cesium-131 patients. The company fails to mention the comparable five-year survival rate for patients undergoing surgery alone is 98% -- a clinically meaningless difference of two percentage points"

The facts again based on the link of the study results in the PR are " the five year overall survival rate for high risk patients with WR+CS131 was 100% whereas it was 97.7% for low risk patients with WR only"

3. AF write "In their conclusion, the study authors do not endorse IsoRay's Cesium-131".

The facts again based on the link of the study results in the PR are "Study authors state that for high risk WRs, we favor use of Cesium-131 brachytherapy".

Now you know who is lazy with the facts. This guy should be ignored from now on by every investor. Less

by r_taparia @ Yahoo message boards